CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Coverage Criteria: Glatiramer acetate (Copaxone, Glatopa) for relapsing multiple sclerosis

Covers use of glatiramer acetate (Copaxone, Glatopa) for FDA-approved relapsing forms of multiple sclerosis and clinically isolated syndrome for adult members when approval criteria are met; excludes non‑approved indications.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyGlatiramer acetate (Copaxone, Glatopa) for relapsing multiple sclerosis

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization for up to 12 months and document prescriber specialty and diagnosis.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthstypical authorization period

adultspatient age group in FDA indication

relapsing MScovered indication

clinically isolated syndromecovered indication

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial and Continuation Therapy

Covered when ALL of the following are met:

FDA-approved indication: Patient has a relapsing form of multiple sclerosis (including clinically isolated syndrome, relapsing-remitting disease, or active secondary progressive disease) in an adult

FDA-approved uses only

Prescriber specialty: Medication is prescribed by or in consultation with a neurologist

Authorization period - Initial therapy: Request for initial authorization is for up to 12 months12 months

Authorization period - Continuation therapy: Continuation requests include documentation of disease stability or improvement and are eligible for up to 12 months authorization12 months

Continuation requires documentation of disease stability or improvement

Provider Actions and Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required. Authorizations may be granted for 12 months for initial and continuation therapy when criteria are met.

Authorization duration: up to 12 months for initial and continuation therapy when medical necessity criteria are satisfied

Denial Risk

Concomitant Therapy Restriction

Members must not use glatiramer products concomitantly with other disease-modifying multiple sclerosis (MS) agents. Exceptions and rationale: Ampyra and Nuedexta are not disease-modifying agents and are not included in this restriction.

Affected products: Copaxone, Glatopa, glatiramer acetate
Exception: Ampyra and Nuedexta are not disease-modifying and are not subject to this restriction

Documentation Required

Required Documentation

Prescriptions must be written by or in consultation with a neurologist. Documentation required for authorization includes the diagnosis (relapsing forms of MS or clinically isolated syndrome) and records demonstrating medical necessity (e.g., prior treatments, clinical notes showing relapse history or disease stability/improvement for continuation).

Prescriber specialty: must be prescribed by or in consultation with a neurologist
Required documentation: diagnosis (relapsing forms of MS or clinically isolated syndrome), relevant clinical notes, prior treatment history, and evidence of disease stability or improvement for continuation requests
Authorization length: requests should indicate the need for up to 12 months of therapy when criteria are met

Denial Risk

Non‑Approved Indications

Requests for indications other than FDA‑approved relapsing forms of MS (including clinically isolated syndrome, relapsing‑remitting disease, and active secondary progressive disease) and compendial uses are considered experimental/investigational and are not covered.

Non‑approved indications are not medically necessary and will be denied

Denial Risk

Concomitant DMT Use Not Allowed

Concomitant use of glatiramer products with other disease‑modifying MS agents is not allowed and may result in denial of the authorization.

Do not prescribe Copaxone, Glatopa, or glatiramer acetate together with other disease‑modifying MS therapies
Denial risk: concurrent DMT use is grounds for denial of the request

Definitions

Relapsing forms of multiple sclerosis — definition

DefinitionRelapsing forms of multiple sclerosis include clinically isolated syndrome, relapsing‑remitting disease, and active secondary progressive disease (FDA‑approved indication).

Age groupAdults (per FDA‑approved indication).

Coverage implicationOnly the FDA‑approved relapsing forms of MS are covered; all other indications are considered experimental/investigational and not medically necessary.

Typical authorizationAuthorizations for these indications may be granted for up to 12 months for initial and continuation therapy when criteria are met.

Prescriber requirementMedication must be prescribed by or in consultation with a neurologist (per policy requirements).

OpenPayer

Coverage Criteria: Glatiramer acetate (Copaxone, Glatopa) for relapsing multiple sclerosis

Coverage Criteria

Provider Actions and Requirements

Background

Definitions